vidprevtyn
Preclinical
AbbVievidprevtyn is one of 3 therapeutic programs targeting RSV. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
2
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
3 competitors in RSV
#DrugCompanyPhaseTrials
1Abrysvo
Johnson & JohnsonApproved
Mrna-1345
ModernaPhase 3
vidprevtyn
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for vidprevtyn. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company